This article is more than 5 years old. Information may no longer be current.

Sirion Therapeutics acquires license to develop new topical cyclosporine product

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TAMPA, Fla. — Sirion Therapeutics Inc. has reached an exclusive licensing agreement with Mexico-based Laboratorios Sophia S.A. de C.V. for the U.S. rights to develop and market a new topical cyclosporine A ophthalmic solution, the company announced.

Sirion officials said the company plans to initiate a clinical program for the product, designated ST-603, in the first half of 2007. “We think the unique properties of the ST-603 formulation can position it to gain significant market share in the U.S. ophthalmic cyclosporine market,” Barry Butler, CEO for Sirion, said in a press release.

Under the agreement, Sirion will have the rights to develop, use, obtain governmental approval for, manufacture, sell, distribute and promote ST-603 throughout the U.S. and all U.S. territories and possessions. The new compound will be formulated for use in the Sophisen ocular drug delivery system. Other terms of the license agreement were not disclosed.